Ankündigung • Jun 30
Novogene Co., Ltd. to Report First Half, 2026 Results on Aug 14, 2026 Novogene Co., Ltd. announced that they will report first half, 2026 results on Aug 14, 2026 New Risk • Jun 26
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Declared Dividend • Jun 05
Dividend of CN¥0.045 announced Shareholders will receive a dividend of CN¥0.045. Ex-date: 10th June 2026 Payment date: 10th June 2026 Dividend yield will be 0.3%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (11% earnings payout ratio) and cash flows (14% cash payout ratio). The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 70% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Tianfan Wang was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Apr 15
Novogene Co., Ltd. announced that it expects to receive CNY 300 million in funding Novogene Co., Ltd. has announced private placement to issue A shares not more than 30% of total share capital at an issue price of not less than 80% of the average price in the 20 trading days before the pricing reference date for gross proceeds not more then CNY 300,000,000 on April 15, 2026. The transaction will include investor participation not more than 35 investors. The transaction is approved by 4th directorate in 6th meeting of proposal about submitting a proposal to the shareholders meeting to authorize the directorate to Implement a simplified private placement of shares. The transaction is subject to approval of company’s annual shareholders. All the securities issued in the offering is subject to a hold period of 6 months from date of issuance. Ankündigung • Apr 14
Novogene Co., Ltd., Annual General Meeting, May 08, 2026 Novogene Co., Ltd., Annual General Meeting, May 08, 2026, at 13:30 China Standard Time. Location: The Company's Multi-function Hall, Beijing China Ankündigung • Mar 30
Novogene Co., Ltd. to Report Q1, 2026 Results on Apr 15, 2026 Novogene Co., Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026 Ankündigung • Dec 26
Novogene Co., Ltd. to Report Fiscal Year 2025 Results on Apr 15, 2026 Novogene Co., Ltd. announced that they will report fiscal year 2025 results on Apr 15, 2026 Ankündigung • Nov 07
Novogene Expands UK Offerings with Launch of ONT-Based Whole Plasmid Sequencing Service Novogene Europe announced the launch of its new Whole Plasmid Sequencing service, powered by Oxford Nanopore Technologies (ONT). This service offering represents a major step forward in plasmid verification, providing researchers with a powerful and practical alternative to traditional Sanger sequencing. Unlike conventional approaches, whole plasmid sequencing delivers a complete, end-to-end view of plasmid constructs, revealing structural variants, rearrangements, and repetitive regions that often remain undetected with first-generation sequencing methods. The service is designed to support scientists working in gene and cell therapy, RNA therapeutics, and synthetic biology, enabling faster, more confident plasmid validation. Novogene's Whole Plasmid Sequences service provides full coverage for plasmids up to tens of kilobases in length, ensuring complete and accurate characterisation. With a streamlined workflow, researchers can benefit from next-day turnaround and high-quality, long-read data. The platform offers flexible throughput, from single plasmids to full 96-well plates using barcoding, making it suitable for both small-scale and high-throughput projects. Designed with accessibility and reliability in mind, the service combines competitive pricing with sequencing performed locally in Novogene's Cambridge (UK) laboratory, ensuring consistent quality, rapid delivery, and simplified logistics for customers across Europe. Complementing this new service is Novogene's broad sequencing portfolio, which includes microbial sequencing, RNA-seq, whole genome sequencing (WGS), long-amplicon analysis, and single-cell sequencing. This integration enables seamless plasmid validation alongside downstream genomic applications, all under one provider. With the introduction of ONT-based plasmid sequencing, Novogene further strengthens its position as a trusted hub for advanced sequencing solutions, expanding its capabilities in both long- and short-read technologies to meet the evolving needs of Europe's life sciences research community. Ankündigung • Sep 30
Novogene Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025 Novogene Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025 Ankündigung • Jun 30
Novogene Co., Ltd. to Report First Half, 2025 Results on Aug 15, 2025 Novogene Co., Ltd. announced that they will report first half, 2025 results on Aug 15, 2025 Ankündigung • Apr 15
Novogene Co., Ltd., Annual General Meeting, May 07, 2025 Novogene Co., Ltd., Annual General Meeting, May 07, 2025, at 13:30 China Standard Time. Location: The Company's Multi-function Hall, Beijing China Ankündigung • Mar 28
Novogene Co., Ltd. to Report Q1, 2025 Results on Apr 15, 2025 Novogene Co., Ltd. announced that they will report Q1, 2025 results on Apr 15, 2025 Ankündigung • Dec 27
Novogene Co., Ltd. to Report Fiscal Year 2024 Results on Apr 15, 2025 Novogene Co., Ltd. announced that they will report fiscal year 2024 results on Apr 15, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.12 in 3Q 2023). Revenue: CN¥522.5m (up 4.7% from 3Q 2023). Net income: CN¥56.5m (up 13% from 3Q 2023). Profit margin: 11% (in line with 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥12.09, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 22x in the Life Sciences industry in China. Total loss to shareholders of 45% over the past year. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Ankündigung • Sep 30
Novogene Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Novogene Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to CN¥11.39, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 21x in the Life Sciences industry in China. Total loss to shareholders of 49% over the past year. Reported Earnings • Aug 15
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.13 in 2Q 2023). Revenue: CN¥528.2m (up 7.9% from 2Q 2023). Net income: CN¥50.6m (down 3.7% from 2Q 2023). Profit margin: 9.6% (down from 11% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Ankündigung • Jun 29
Novogene Co., Ltd. to Report First Half, 2024 Results on Aug 15, 2024 Novogene Co., Ltd. announced that they will report first half, 2024 results on Aug 15, 2024 Buy Or Sell Opportunity • Apr 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 32% to CN¥12.81. The fair value is estimated to be CN¥16.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has declined by 3.4%. Revenue is forecast to grow by 43% in 2 years. Earnings are forecast to grow by 50% in the next 2 years. Reported Earnings • Apr 16
First quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.06 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.06 in 1Q 2023). Revenue: CN¥468.5m (up 6.3% from 1Q 2023). Net income: CN¥27.3m (up 21% from 1Q 2023). Profit margin: 5.8% (up from 5.1% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Ankündigung • Apr 13
Novogene Co., Ltd., Annual General Meeting, May 06, 2024 Novogene Co., Ltd., Annual General Meeting, May 06, 2024, at 13:30 China Standard Time. Ankündigung • Mar 29
Novogene Co., Ltd. to Report Q1, 2024 Results on Apr 13, 2024 Novogene Co., Ltd. announced that they will report Q1, 2024 results on Apr 13, 2024 Reported Earnings • Feb 28
Full year 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.44 in FY 2022) Full year 2023 results: EPS: CN¥0.44. Revenue: CN¥2.00b (up 4.0% from FY 2022). Net income: CN¥177.4m (flat on FY 2022). Profit margin: 8.9% (down from 9.2% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Life Sciences industry in China. Ankündigung • Feb 08
Novogene Co., Ltd. (SHSE:688315) announces an Equity Buyback for CNY 160 million worth of its shares. Novogene Co., Ltd. (SHSE:688315) announces a share repurchase program. Under the program, the company will repurchase up to CNY 160 million worth of its shares. The shares will be repurchased at no more than CNY 28.53 per share. The purpose of the program is to use the repurchased shares for equity incentives or employee stock ownership plans. If the company fails to use the shares for said purpose with in three years of completion of the plan, the unused shares will be cancelled. The program will be funded from company's own funds. The plan will be valid for 12 months. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥14.61, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 20x in the Life Sciences industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥14.81 per share. Buy Or Sell Opportunity • Jan 23
Now 20% overvalued Over the last 90 days, the stock has fallen 15% to CN¥17.91. The fair value is estimated to be CN¥14.87, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 60% in 2 years. Earnings are forecast to grow by 63% in the next 2 years. New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Shareholders have been diluted in the past year (4.0% increase in shares outstanding). New Risk • Dec 04
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. New Risk • Oct 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.14 in 3Q 2022). Revenue: CN¥499.2m (down 3.1% from 3Q 2022). Net income: CN¥50.2m (down 11% from 3Q 2022). Profit margin: 10% (in line with 3Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in China. Valuation Update With 7 Day Price Move • Aug 08
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥22.84, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 24x in the Life Sciences industry in China. Ankündigung • Jun 28
Novogene Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023 Novogene Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023 Reported Earnings • Apr 13
First quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.07 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.06 (down from CN¥0.07 in 1Q 2022). Revenue: CN¥440.6m (up 3.7% from 1Q 2022). Net income: CN¥22.5m (down 21% from 1Q 2022). Profit margin: 5.1% (down from 6.7% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Life Sciences industry in China. 
